Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Conclusion The HT receptor family
2024-10-19

Conclusion The 5-HT receptor family is complex, and one may ask as does Bryan Roth et al. [205] whether this is useless TAK 165 mg (i.e. too much redundancy) or an embarrassment of the riches (i.e. many potential targets to choose from to affect normal or pathological function); molecular biolog
-
Despite functional studies demonstrating the role of HT in u
2024-10-19

Despite functional studies demonstrating the role of 5-HT in ureteral contractility, the source of endogenous 5-HT in the ureter is unclear. Since 5-HT-containing enterochromaffin cells, which are present in the gastrointestinal tract, could not be found in the ureter (Nocito et al., 2007, Ripoche,
-
Adenosine is a ubiquitous homeostatic
2024-10-19

Adenosine is a ubiquitous homeostatic substance released from most cells, including neurons and glias. Endogenous adenosine acts at four principal G-protein-associated receptor subtypes: A1, A2a, A2b and A3 (Ralevic and Burnstock, 1998). The stimulation of adenosine receptors by extracellular adenos
-
Although the effects of adenosine receptor signaling
2024-10-19

Although the effects of adenosine receptor signaling in acute renal IRI have been attributed to the generation of high concentrations of adenosine, we have recently reported an increase in kidney levels of both AMP and adenosine, with a concomitant fall in ATP and ADP. We have also previously demons
-
A more versatile cellular delivery system for adenosine was
2024-10-19

A more versatile cellular delivery system for adenosine was generated by engineering mouse embryonic stem cells to lack both ctep of Adk (Fedele et al., 2004). Using a step-wise differentiation protocol (Okabe et al., 1996) Adk−/− ES cells were differentiated into transplantable adenosine-releasing
-
It is interesting that Li et al reported that AChR
2024-10-19

It is interesting that Li et al. (2008) reported that AChR-immunized FcγRIIB knock out (KO) mice are significantly resistant to antibody-mediated EAMG. This is in contrast with previous studies, but does not contradict the results presented here. Despite their observation that the incidence and seve
-
The results show that a tonic action of
2024-10-19

The results show that a tonic action of ACh on respiration is lacking. However, it is clear that muscarinic cholinergic mechanisms can modulate both eupneic breathing and the cough reflex. When these mechanisms are brought into action is obscure and only tentative proposals can be advanced. ACh in t
-
However for a molecular target to be
2024-10-19

However, for a molecular target to be useful in AD, it must rescue behavioral as well as biochemical insults. In humans, AD memory impairments typically declare themselves initially as disruption of episodic memory and consolidation of new memories, eventually progressing to global cognitive decline
-
In addition to the data provided by the Ki
2024-10-19

In addition to the data provided by the Ki16425 treatment in the K/BxN arthritis model, new findings from the study of two new LPA receptor antagonists confirm the involvement of the LPA pathway in the pathogenesis of experimental arthritis. In the study by Miyabe et al., the authors reported the tr
-
In this study we observed
2024-10-19

In this study, we observed the ATPase activity of RaGroEL at various temperatures and metal ions conditions and the role of GroES in the ATPase activity of RaGroEL. Furthermore, we quantified the expression of groEL genes under different abiotic stresses, including temperature, pH, salt and oxygen s
-
br Materials and Methods br Results br Discussion HETE
2024-10-19

Materials and Methods Results Discussion 15-HETE is a predominant eicosanoid in pulmonary vascular remodeling, and it could promote hypoxia-induced PAH via its involvement in the regulation of proliferation and cell cycle progression in PASMCs. To understand its role in HPH, we have previou
-
In addition to connecting high ARG
2024-10-19

In addition to connecting high ARG1 levels with DNMT3A/TET2 mutations in MDS/CMML patient biopsies, we also wanted to address the cell type demonstrating elevated ARG1. Following our mouse work, we hypothesized that overexpression of this protein would be found in myelomonocytic Gallein including m
-
Overall we found maternal antibiotics to be associated with
2024-10-18

Overall, we found maternal ISRIB to be associated with improved outcomes. In these multiple logistic regression models, high postnatal empiric infant antibiotic exposure was not significantly associated with risk for NEC or LOS. However, consistent with previous studies,5, 6 receipt of high empiric
-
Intriguingly androgens may also have an indirect effect
2024-10-18

Intriguingly androgens may also have an indirect effect on AR gene expression through inhibition of the GATA2 transcription factor gene (He et al., 2014) (Table 1). Using ChIP-seq, GATA2 was found to bind to a regulatory element 5.5 kb upstream of the TSS of the AR gene and enhanced transcription, w
-
PTC209 HBr The major phase trial NCT enrolled
2024-10-18

The major phase 2 trial (NCT01343966) enrolled 431 participants with mild to moderate AD who received either low-dose SC crenezumab 300 mg or placebo biweekly (n = 184) or high-dose intravenous crenezumab 15 mg/kg or placebo every 4 weeks (n = 247) for 68 weeks 38, 40. No significant treatment benef
15937 records 70/1063 page Previous Next First page 上5页 6667686970 下5页 Last page